Valeant Pharmaceuticals International, Inc. (VRX) Reports Q2 Earnings of $1.01; Guides Slightly Higher
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Less: Net income attributable to noncontrolling interest: 1K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Financial Fact:
Less: Net income attributable to noncontrolling interest: 1K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q2 EPS of $1.01, versus $0.99 reported last year. Revenue for the quarter came in at $820.1 million versus the consensus estimate of $822.7 million.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.55-$4.75, versus prior guidance of $4.45-$4.70 and the consensus of $4.51
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.55-$4.75, versus prior guidance of $4.45-$4.70 and the consensus of $4.51
For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
